Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen -- Ignore unavailable to you. Want to Upgrade?

To: TI2, TechInvestorToo who wrote (3789)	12/30/2000 11:40:12 PM
From: Gary Mohilner	Read Replies (2) \| Respond to of 5665

I liked what I saw in Mitch's message. One thing I have a hard time agreeing with is not considering drugs like C242-DM1 and Herceptin-DM1 a part of our pipeline. True, they are primarily owned by IMGN's partners, but the royalties from them and others could potentially put hundreds of millions in IMGN's coffers annually. I consider that part of the pipeline. In the future IMGN will no doubt own the majority of many drugs, like it does N901-DM1. Having said that, I believe that a substantial percentage of IMGN's income will come from partnerships, both milestones and royalties. I feel that any drug that could put money in our pockets should be considered a part of our pipeline. I'm happy to see we met our end of the year goal in filing the IND, the fact that they didn't issue P.R. about it the day they filed doesn't surprise me. This way if there are minor delays in the approval process, we'll never know about it. Have a Happy, Healthy and Prosperous New Year's everyone, Gary